GlassScriptPhysician profile
Joel I Sarachek
NPI 1518987114
$2,077.71
in general payments reported to CMS, 2019-2025
16 companies · $561 in 2025
The $561 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $722 · 2021: $269 · 2022: $112 · 2023: $151 · 2024: $263 · 2025: $561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $975.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $974.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $440.06 | 2022-2025 | Evenity, Prolia |
| Abbvie INC. | $273.64 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $248.69 | 2019-2021 | |
| Gilead Sciences, INC. | $243.12 | 2023-2025 | Descovy, Yeztugo |
| Lilly USA, LLC | $170.11 | 2019-2025 | Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.19 | 2019 | |
| Novo Nordisk INC | $117.28 | 2025 | Wegovy, Rybelsus, Ozempic |
| Dynavax Technologies Corporation | $114.44 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $111.26 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $75.32 | 2024-2025 | Breztri, Fasenra |
| Pfizer INC. | $51.83 | 2024-2025 | |
| Glaxosmithkline, LLC. | $29.32 | 2025 | Bexsero, Shingrix, Arexvy |
| Abbott Laboratories | $27.63 | 2023 | Afinion 2 |
| Hologic Sales and Service, LLC | $22.45 | 2024 | Aptima, Thinprep 2000 Processor |
| Exact Sciences Corporation | $14.47 | 2025 | The Cologuard Plus Collection Kit |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $13.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Sarachek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.